Table 1.
Baseline characteristics of patients.
| Features | Standard AP (group A) n = 46 |
Prolonged AP (group B) n = 46 |
Р value | |
|---|---|---|---|---|
| Male gender, abs. (%) | 42 (91.3) | 42 (91.3) | 1.0 | |
| Age, М±SD (95% CI), years | 63.4 ± 8.8 (60.8–66.0) | 66.7 ± 8.3 (64.2–69.2) | 0.067 | |
| BMI, Me (Q1-Q3) | 26.9 (24.2–30.0) | 26.2 ± (24.0–29.2) | 0.475 | |
| ECOG status, abs. (%) | ||||
| 0 | 40 (87.0) | 40 (87.0) | 1.0 | |
| 1 | 6 (13.0) | 6 (13.0) | ||
| Availability of drainage**, abs. (%) | 7 (41.2) | 10 (58.8) | 0.592 | |
| Previous treatment | Neoadjuvant therapy, abs. (%) | 30 (65.2) | 30 (65.2) | 1.0 |
| -GC***, abs. (%) | 26 (56.5) | 28 (60.9) | 0.672 | |
| - MVAC***, abs. (%) | 2 (4.3) | 0 (0.0) | 0.495 | |
| -Immunotherapy***, abs. (%) | 2 (4.3) | 2 (4.3) | 1.0 | |
| Urinary diversion (intent-to-treat) | ||||
| -heterotopic, abs. (%) | 40 (87.0) | 39 (84.8) | 1.0 | |
| -orthotopic, abs. (%) | 6 (13.0) | 7 (15.2) | ||
| Histological variant | ||||
| -pure type, abs. (%) | 42 (91.3) | 42 (91.3) | 1.0 | |
| -variant histology, abs. (%) | 4 (8.7) | 4 (8.7) | ||
| cT | Та/is, abs. (%) | 4 (8.7) | 3 (6.5) | 0.772 |
| T1, abs. (%) | 7 (15.2) | 10 (21.7) | ||
| T2, abs. (%) | 15 (32.6) | 17 (37.0) | ||
| T3, abs. (%) | 17 (37.0) | 12 (26.1) | ||
| T4, abs. (%) | 3 (6.5) | 4 (8.7) | ||
| сN | сN0, abs. (%) | 41 (89.1) | 38 (82.6) | 0.551 |
| cN1–3, abs. (%) | 5 (10.9) | 8 (17.4) | ||
| cM | cM0, abs. (%) | 45 (97.8) | 43 (93.5) | 0.617 |
| cM1, abs. (%) | 1 (2.2) | 3 (6.5) | ||
**-presence of installed drainages (nephrostomy) due to obstructed urine outflow; ***GC regimen gemcitabine + cisplatin, MVAC- methotrexate, vinblastine, doxorubicin, cisplatin; Immunotherapy in clinical trial.